pharmaceutical-investing Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
pharmaceutical-investing Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
pharmaceutical-investing PADCEV Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
pharmaceutical-investing Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
pharmaceutical-investing Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
pharmaceutical-investing TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
pharmaceutical-investing Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
pharmaceutical-investing Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
pharmaceutical-investing Arvinas Announces Data Presentations from the Vepdegestrant Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium
pharmaceutical-investing U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
pharmaceutical-investing Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
pharmaceutical-investing Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
American Eagle Drills 802 Metres of 0.71% Copper Eq. from Surface, including 375 Metres of 1.01% Copper Eq.
